Search

Your search keyword '"Filippi, J."' showing total 518 results
Start Over Author "Filippi, J."
518 results on '"Filippi, J."'

4. AB1493 PATIENT SATISFACTION AND EXPERIENCE AFTER A SWITCH TO AN ADALIMUMAB BIOSIMILAR WITH HIGH CONCENTRATION AND CITRATE-FREE: RESULTS FROM A MULTICENTRIC PROSPECTIVE REAL-LIFE STUDY

Author

Marotte, H., primary, Gossec, L., additional, Abitbol, V., additional, Senbel, E., additional, Bonnaud, G., additional, Roblin, X., additional, Bouhnik, Y., additional, Nancey, S., additional, Mathieu, N., additional, Filippi, J., additional, Vuitton, L., additional, Nahon, S., additional, Dellal, A., additional, Denis, A., additional, Habauzit, C., additional, Benkhalifa, S., additional, and Bouguen, G., additional

Published
2024
Full Text
View/download PDF

8. P884 Patient satisfaction and experience after a switch to an adalimumab biosimilar with high concentration and citrate-free: results from a multicentric prospective real-life study

Author

Bouguen, G, primary, Gossec, L, additional, Abitbol, V, additional, Senbel, E, additional, Bonnaud, G, additional, Roblin, X, additional, Bouhnik, Y, additional, Nancey, S, additional, Mathieu, N, additional, Filippi, J, additional, Vuitton, L, additional, Nahon, S, additional, Dellal, A, additional, Denis, A, additional, Habauzit, C, additional, Benkhalifa, S, additional, and Marotte, H, additional

Published
2024
Full Text
View/download PDF

9. Direct Alcohol Fuel Cells: A Comparative Review of Acidic and Alkaline Systems

Author

Berretti, E, Osmieri, L, Baglio, V, Miller, H, Filippi, J, Vizza, F, Santamaria, M, Specchia, S, Santoro, C, Lavacchi, A, Berretti E., Osmieri L., Baglio V., Miller H. A., Filippi J., Vizza F., Santamaria M., Specchia S., Santoro C., Lavacchi A., Berretti, E, Osmieri, L, Baglio, V, Miller, H, Filippi, J, Vizza, F, Santamaria, M, Specchia, S, Santoro, C, Lavacchi, A, Berretti E., Osmieri L., Baglio V., Miller H. A., Filippi J., Vizza F., Santamaria M., Specchia S., Santoro C., and Lavacchi A.

Abstract

In the last 20 years, direct alcohol fuel cells (DAFCs) have been the subject of tremendous research efforts for the potential application as on-demand power sources. Two leading technologies respectively based on proton exchange membranes (PEMs) and anion exchange membranes (AEMs) have emerged: the first one operating in an acidic environment and conducting protons; the second one operating in alkaline electrolytes and conducting hydroxyl ions. In this review, we present an analysis of the state-of-the-art acidic and alkaline DAFCs fed with methanol and ethanol with the purpose to support a comparative analysis of acidic and alkaline systems, which is missing in the current literature. A special focus is placed on the effect of the reaction stoichiometry in acidic and alkaline systems. Particularly, we point out that, in alkaline systems, OH− participates stoichiometrically to reactions, and that alcohol oxidation products are anions. This aspect must be considered when designing the fuel and when making an energy evaluation from a whole system perspective. Graphical Abstract: [Figure not available: see fulltext.]

Published
2023

11. Waste Face Surgical Mask Transformation into Crude Oil and Nanostructured Electrocatalysts for Fuel Cells and Electrolyzers

Author

Muhyuddin, M, Filippi, J, Zoia, L, Bonizzoni, S, Lorenzi, R, Berretti, E, Capozzoli, L, Bellini, M, Ferrara, C, Lavacchi, A, Santoro, C, Muhyuddin M., Filippi J., Zoia L., Bonizzoni S., Lorenzi R., Berretti E., Capozzoli L., Bellini M., Ferrara C., Lavacchi A., Santoro C., Muhyuddin, M, Filippi, J, Zoia, L, Bonizzoni, S, Lorenzi, R, Berretti, E, Capozzoli, L, Bellini, M, Ferrara, C, Lavacchi, A, Santoro, C, Muhyuddin M., Filippi J., Zoia L., Bonizzoni S., Lorenzi R., Berretti E., Capozzoli L., Bellini M., Ferrara C., Lavacchi A., and Santoro C.

Abstract

A novel route for the valorization of waste into valuable products was developed. Surgical masks commonly used for COVID 19 protection by stopping aerosol and droplets have been widely used, and their disposal is critical and often not properly pursued. This work intended to transform surgical masks into platinum group metal-free electrocatalysts for oxygen reduction reaction (ORR) and hydrogen evolution reaction (HER) as well as into crude oil. Surgical masks were subjected to controlled-temperature and -atmosphere pyrolysis, and the produced char was then converted into electrocatalysts by functionalizing it with metal phthalocyanine of interest. The electrocatalytic performance characterization towards ORR and HER was carried out highlighting promising activity. At different temperatures, condensable oil fractions were acquired and thoroughly analyzed. Transformation of waste surgical masks into electrocatalysts and crude oil can open new routes for the conversion of waste into valuable products within the core of the circular economy.

Published
2022

14. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab

Author

Laharie, D, Bourreille, A, Branche, J, Allez, M, Bouhnik, Y, Filippi, J, Zerbib, F, Savoye, G, Vuitton, L, Moreau, J, Amiot, A, Cosnes, J, Ricart, E, Dewit, O, Lopez-Sanroman, A, Fumery, M, Carbonnel, F, Bommelaer, G, Coffin, B, Roblin, X, van Assche, G, Esteve, M, Farkkila, M, Gisbert, JP, Marteau, P, Nahon, S, de Vos, M, Lambert, J, Mary, JY, and Louis, E

Published
2018
Full Text
View/download PDF

15. Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort

Author

Tadbiri, S., Peyrin‐Biroulet, L., Serrero, M., Filippi, J., Pariente, B., Roblin, X., Buisson, A., Stefanescu, C., Trang‐Poisson, C., Altwegg, R., Marteau, P., Vaysse, T., Bourrier, A., Nancey, S., Laharie, D., Allez, M., Savoye, G., Gilletta, C., Gagniere, C., Vuitton, L., Viennot, S., Aubourg, A., Pelletier, A.‐L., Bouguen, G., Abitbol, V., Fumery, M., Claudepierre, P., Bouhnik, Y., Amiot, A., Amiot, Aurelien, Gagniere, Charlotte, Serrero, Melanie, Grimaud, Jean‐Charles, Peyrin‐Biroulet, Laurent, Zallot, Camille, Bigard, Marc‐Andre, Filippi, Jerome, Hebuterne, Xavier, Pariente, Benjamin, Nachury, Maria, Desreumaux, Pierre, Roblin, Xavier, Del Tedesco, Emilie, Buisson, Anthony, Bommelaer, Gilles, Stefanescu, Carmen, Bouhnik, Yoram, Boureille, Arnaud, Trang‐Poisson, Caroline, Altwegg, Romain, Marteau, Philippe, Dray, Xavier, Carbonnel, Franck, Vaysse, Thibaud, Seksik, Philippe, Beaugerie, Laurent, Cosnes, Jacques, Sokol, Harry, Landman, Cecilia, Bourrier, Anne, Nancey, Stephane, Boschetti, Gilles, Laharie, David, Poullenot, Florian, Allez, Matthieu, Gornet, Jean‐Marc, Baudry, Clautilde, Savoye, Guillaume, Moreau, Jacques, Vuitton, Lucine, Koch, Stephane, Viennot, Stephanie, Aubourg, Alexandre, Picon, Laurence, Pelletier, Anne‐Laure, Sickersen, Gaelle, Bouguen, Guillaume, Abitbol, Vered, Chaussade, Stanislas, Fumery, Mathurin, Nahon, Stephane, Winkfield, Betsy, Brixi‐benmansour, Hedia, Gincul, Rodica, Barberis, Jean‐Christophe, Bonaz, Bruno, Michiels, Christophe, Zerbib, Franck, Bourrier de Beauregard, Marie, Locher, Christophe, Davin‐Couve, Sophie, Poirette, Armelle, Guillem, Laurence, Stetiu‐Mocanu, Monica, Philippe, Beau, Beorchia, Sylvain, and Al Qaddi, Jawad

Published
2018
Full Text
View/download PDF

16. Synthesis of 2D anatase TiO2 with highly reactive facets by fluorine-free topochemical conversion of 1T-TiS2 nanosheets

Author

Zarattini, M, Dun, C, Isherwood, L, Felten, A, Filippi, J, Gordon, M, Zhang, L, Kassem, O, Song, X, Zhang, W, Ionescu, R, Wittkopf, J, Baidak, A, Holder, H, Santoro, C, Lavacchi, A, Urban, J, Casiraghi, C, Isherwood, LH, Gordon, MP, Wittkopf, JA, Urban, JJ, Zarattini, M, Dun, C, Isherwood, L, Felten, A, Filippi, J, Gordon, M, Zhang, L, Kassem, O, Song, X, Zhang, W, Ionescu, R, Wittkopf, J, Baidak, A, Holder, H, Santoro, C, Lavacchi, A, Urban, J, Casiraghi, C, Isherwood, LH, Gordon, MP, Wittkopf, JA, and Urban, JJ

Abstract

Two-dimensional (2D) anatase titanium dioxide (TiO2) is expected to exhibit different properties as compared to anatase nanocrystallites, due to its highly reactive exposed facets. However, access to 2D anatase TiO2 is limited by the non-layered nature of the bulk crystal, which does not allow use of top-down chemical exfoliation. Large efforts have been dedicated to the growth of 2D anatase TiO2 with high reactive facets by bottom-up approaches, which relies on the use of harmful chemical reagents. Here, we demonstrate a novel fluorine-free strategy based on topochemical conversion of 2D 1T-TiS2 for the production of single crystalline 2D anatase TiO2, exposing the {001} facet on the top and bottom and {100} at the sides of the nanosheet. The exposure of these faces, with no additional defects or doping, gives rise to a significant activity enhancement in the hydrogen evolution reaction, as compared to commercially available Degussa P25 TiO2 nanoparticles. Because of the strong potential of TiO2 in many energy-based applications, our topochemical approach offers a low cost, green and mass scalable route for production of highly crystalline anatase TiO2 with well controlled and highly reactive exposed facets.

Published
2022

21. Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?

Author

Filippi, J., Altwegg, R., Hebuterne, X., Boschetti, G., Veyrard, P., Yzet, Clara, Paul, S., Roblin, X., Fumery, Mathurin, Nancey, S., Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département de Gastroentérologie, Hôpital de l'Archet 2, Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Amiens-Picardie, Simplification des soins chez les patients complexes - UR UPJV 7518 (SSPC), Université de Picardie Jules Verne (UPJV), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), and Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2022

22. P140 Immunomodulators are protective against severe COVID 19: results from a large multicentre cohort of inflammatory bowel disease patients

Author

Vuitton, L, primary, Bourrier, A, additional, Uzzan, M, additional, Nachury, M, additional, Amiot, A, additional, Roblin, X, additional, Allez, M, additional, Altwegg, R, additional, Vidon, M, additional, Bourreille, A, additional, Serrero, M, additional, Pelletier, A L, additional, Filippi, J, additional, Gilletta, C, additional, Simon, M, additional, Laharie, D, additional, Nahon, S, additional, Duveau, N, additional, Biron, A, additional, Viennot, S, additional, Abitbol, V, additional, Elgharabawy, Y, additional, and Peyrin-Biroulet, L, additional

Published
2022
Full Text
View/download PDF

23. DOP36 Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study

Author

Sallette, M, primary, Bouhnik, Y, additional, Nachury, M, additional, Bellanger, C, additional, Laharie, D, additional, Amiot, A, additional, Peyrin-Biroulet, L, additional, Roblin, X, additional, Altwegg, R, additional, Buisson, A, additional, Reenaers, C, additional, Bouguen, G, additional, Vuitton, L, additional, Bourreille, A, additional, Gilletta, C, additional, Serrero, M, additional, Hébuterne, X, additional, and Filippi, J, additional

Published
2022
Full Text
View/download PDF

28. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study

Author

Fumery, Mathurin, Filippi, J., Abitbol, V., Biron, A., Laharie, D., Serrero, M., Altwegg, R., Bouhnik, Y., Peyrinbiroulet, L., Gilletta, C., Roblin, X., Chambrun, G. Pineton, Vuitton, L., Bourrier, A., Nancey, S., Gornet, J. M., Nahon, S., Bouguen, G., Viennot, S., Pariente, B., Amiot, A., Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Clichy, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Pasteur [Nice] (CHU), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpital Claude Huriez [Lille], CHU Lille, and CHU Henri Mondor [Créteil]

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; Background: Phase III trials have demonstrated the efficacy and safety of ustekinumab in moderate-to-severe ulcerative colitis (UC), but no real-life long-term data is currently available. Methods: From January to September 2019, all consecutive patients with active UC treated with ustekinumab in a GETAID centre were included. Patients were evaluated at week 52. Remission was defined by a partial Mayo Clinic score ≤ 2. The aim of the present study was to assess long-term effectiveness and safety of usteki numab in UC. Results: 103 UC patients (62 men; mean age: 41.2 ± 16.2 years; 52% pancolitis E3) were included in 21 centres. History of immunomodulator, anti-TNF and vedolizumab therapies was noted in 84.5%, 99.0% and 85.4% of the cases, respectively. At week 54, 44 (43%) patients discontinued ustekinumab, for lack of efficacy (n=41), pregnancy (n=1), persistence of eczematiform lesions (n=1) or personal decision (n=1). Cumulative probabilities of ustekinumab persistence were 96.1%, 81.6%, 71.7%, and 58.4% after 3, 6, 9, and 12 months, respectively. In multivariate analysis, a CRP>5 mg/L at week 0 (OR=2.91, CI95%[1.15–7.36]; p=0.02) and concomitant steroids at week 0 (OR=3.05, CI95%[1.30–7.14]; p=0.01) were significantly associated with ustekinumab discontinuation within one year. The overall rate of steroid-free clinical remission at week 52 was 32% of whom 71% had null rectal bleeding and stool frequency Downloaded from https://academic.oup.com/ecco-jcc/article/15/Supplement_1/S486/6286779 by guest on 03 February 2022 Abstracts of the 16th Congress of ECCO - European Crohn's and Colitis Organisation S487 subscores. Ten patients (9.7%) underwent colectomy within a median of 6.7 [4.3–10.6] months. Adverse events were observed in 15 (16.9%) patients, of whom 4 (4.5%) had severe adverse events including three patients with exacerbation of UC leading to hospitalization, and a 62 years-old men who died from a myocardial infarction four months after ustekinumab initiation. Conclusion: In this real-world cohort study that included patients with refractory ulcerative colitis to multiple therapies, more than one-half of patients were still treated by ustekinumab and one-third were in steroid-free clinical remission, after 52 weeks.

Published
2021

31. P504 Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study

Author

Fumery, M, primary, Filippi, J, additional, Abitbol, V, additional, Biron, A, additional, Laharie, D, additional, Serrero, M, additional, Altwegg, R, additional, Bouhnik, Y, additional, Peyrinbiroulet, L, additional, Gilletta, C, additional, Roblin, X, additional, Pineton de Chambrun, G, additional, Vuitton, L, additional, Bourrier, A, additional, Nancey, S, additional, Gornet, J M, additional, Nahon, S, additional, Bouguen, G, additional, Viennot, S, additional, Pariente, B, additional, and Amiot, A, additional

Published
2021
Full Text
View/download PDF

32. Efficient Electrochemical Water Splitting with PdSn4Dirac Nodal Arc Semimetal

Author

Boukhvalov, D. W., Kuo, C. -N., Nappini, S., Marchionni, A., D’Olimpio, G., Filippi, J., Mauri, S., Torelli, P., Lue, C. S., Vizza, F., Politano, A., Boukhvalov, D. W., Kuo, C. -N., Nappini, S., Marchionni, A., D’Olimpio, G., Filippi, J., Mauri, S., Torelli, P., Lue, C. S., Vizza, F., and Politano, A.

Abstract

Recently, several researchers have claimed the existence of superior catalytic activity associated with topological materials belonging to the class of Dirac/Weyl semimetals, owing to the high electron conductivity and charge carrier mobility in these topological materials. By means of X-ray photoelectron spectroscopy, electrocatalytic tests, and density functional theory, we have investigated the chemical reactivity (chemisorption of ambient gases), ambient stability, and catalytic properties of PdSn4, a topological semimetal showing Dirac node arcs. We find a Tafel slope of 83 mV in the hydrogen evolution reaction (HER) dec-1with an overpotential of 50 mV, with performances resembling those of pure Pd, regardless of its limited amount in the alloy, with a subsequent reduction in the cost of raw materials by ∼80%. Remarkably, the PdSn4-based electrode shows superior robustness to CO compared to pure Pd and Pt and high stability in water media, although the PdSn4surface is prone to oxidation with the formation of a sub-nanometric SnO2skin. Moreover, we also assessed the significance of the role of topological electronic states in the observed catalytic properties. Actually, the peculiar atomic structure of oxidized PdSn4enables the migration of hydrogen atoms through the Sn-O layer with a barrier comparable with the energy cost of the Heyrovsky step of HER over Pt(111) in acidic media (0.1 eV). On the other hand, the topological properties play a minor role, if existing, contrarily to the recent reports overestimating their contribution in catalytic properties. © 2021 The Authors. Published by American Chemical Society

Published
2021

34. Machine learning phenomics (MLP) combining deep learning with time-lapse-microscopy for monitoring colorectal adenocarcinoma cells gene expression and drug-response.

Author

D'Orazio, M., Murdocca, M., Mencattini, A., Casti, P., Filippi, J., Antonelli, G., Di Giuseppe, D., Comes, M. C., Di Natale, C., Sangiuolo, F., and Martinelli, E.

Subjects
MACHINE learning, DEEP learning, GENE expression, ADENOCARCINOMA, SOFTWARE architecture, ANTINEOPLASTIC agents
Abstract

High-throughput phenotyping is becoming increasingly available thanks to analytical and bioinformatics approaches that enable the use of very high-dimensional data and to the availability of dynamic models that link phenomena across levels: from genes to cells, from cells to organs, and through the whole organism. The combination of phenomics, deep learning, and machine learning represents a strong potential for the phenotypical investigation, leading the way to a more embracing approach, called machine learning phenomics (MLP). In particular, in this work we present a novel MLP platform for phenomics investigation of cancer-cells response to therapy, exploiting and combining the potential of time-lapse microscopy for cell behavior data acquisition and robust deep learning software architectures for the latent phenotypes extraction. A two-step proof of concepts is designed. First, we demonstrate a strict correlation among gene expression and cell phenotype with the aim to identify new biomarkers and targets for tailored therapy in human colorectal cancer onset and progression. Experiments were conducted on human colorectal adenocarcinoma cells (DLD-1) and their profile was compared with an isogenic line in which the expression of LOX-1 transcript was knocked down. In addition, we also evaluate the phenotypic impact of the administration of different doses of an antineoplastic drug over DLD-1 cells. Under the omics paradigm, proteomics results are used to confirm the findings of the experiments. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome

Author

Piche, T., Saint-Paul, M.C., Dainese, R., Marine-Barjoan, E., Iannelli, A., Montoya, M.L., Peyron, J.F., Czerucka, D., Cherikh, F., Filippi, J., Tran, A., and Hebuterne, X.

Subjects
Irritable bowel syndrome -- Development and progression, Irritable bowel syndrome -- Psychological aspects, Irritable bowel syndrome -- Research, Fatigue -- Development and progression, Depression, Mental -- Development and progression, Mast cells -- Physiological aspects, Mast cells -- Research, Health
Published
2008

37. Effectiveness and safety of ustekinumab induction therapy in ulcerative colitis: A GETAID real-world cohort study

Author

Amiot, A., Vered, A., Filippi, J., Cadiot, G., Laharie, D., Melanie, S., Altwegg, R., Bouhnik, Y., Peyrin-Biroulet, L., Gilletta, C., Roblin, X., Chambrun, G. Pineton, Vuitton, L., Bourrier, A., Nancey, S., Gornet, J. M., Nahon, S., Bouguen, G., Viennot, S., Benjamin, P., Fumery, Mathurin, DESSAIVRE, Louise, Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier Universitaire de Reims (CHU Reims), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'Hépato-gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital Pasteur [Nice] (CHU), CHU Pontchaillou [Rennes], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), and Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

38. Multicenter randomized double-blind cinical trial assessing the benefit of adherent-invasive E. coli eradication in adult ileal and ileo-colonic Crohn disiease: the teorem trial

Author

Carbonel, F., Vazeille, Emilie, Filippi, J, Bouhnik, Y, Moreau, J, Pariente, B, Michiels, C, Cadiot, G., Pineton de Chambrun, Guillaume, Allez, Michel, Barnich, Nicolas, Chevret, S, Buisson, Anthony, OUERTANI, jeannette, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, [SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

39. Defining and Assessing the Reproducibility of Crohn’s Disease Endoscopic Lesions: A Delphi-like Method from the GETAID

Author

Buisson, A, primary, Filippi, J, additional, Amiot, A, additional, Cadiot, G, additional, Allez, M, additional, Marteau, P, additional, Bouhnik, Y, additional, Pineton de Chambrun, G, additional, Pelletier, A L, additional, Nancey, S, additional, Moussata, D, additional, Attar, A, additional, Blain, A, additional, Vuitton, L, additional, Vernier-Massouille, G, additional, Seksik, P, additional, Nachury, M, additional, Dupas, J L, additional, Laharie, D, additional, Peyrin-Biroulet, L, additional, Louis, E, additional, and Mary, J Y, additional

Published
2020
Full Text
View/download PDF

42. Multi-scale generative adversarial network for improved evaluation of cell–cell interactions observed in organ-on-chip experiments

Author

Comes, M. C., primary, Filippi, J., additional, Mencattini, A., additional, Casti, P., additional, Cerrato, G., additional, Sauvat, A., additional, Vacchelli, E., additional, De Ninno, A., additional, Di Giuseppe, D., additional, D’Orazio, M., additional, Mattei, F., additional, Schiavoni, G., additional, Businaro, L., additional, Di Natale, C., additional, Kroemer, G., additional, and Martinelli, E., additional

Published
2020
Full Text
View/download PDF

43. P730 Effectiveness and safety of endoscopic balloon dilation of colorectal strictures in Crohn’s disease

Author

TILMANT, M, primary, serrero, M, additional, Poullenot, F, additional, Bouguen, G, additional, Pariente, B, additional, Altwegg, R, additional, Basile, P, additional, Filippi, J, additional, Vanelslander, P, additional, Buisson, A, additional, Vuitton, L, additional, Desjeux, A, additional, Laharie, D, additional, Le Balch, E, additional, Nachury, M, additional, Boivineau, L, additional, Savoye, G, additional, Hebuterne, X, additional, Poincloux, L, additional, Lamrani, A, additional, and Fumery, M, additional

Published
2020
Full Text
View/download PDF

44. P719 Effectiveness and safety of ustekinumab induction therapy in ulcerative colitis: A GETAID real-world cohort study

Author

Amiot, A, primary, Vered, A, additional, Filippi, J, additional, Cadiot, G, additional, Laharie, D, additional, Melanie, S, additional, Altwegg, R, additional, Bouhnik, Y, additional, Peyrin-biroulet, L, additional, Gilletta, C, additional, Roblin, X, additional, Pineton de chambrun, G, additional, Vuitton, L, additional, Bourrier, A, additional, Nancey, S, additional, Gornet, J M, additional, Nahon, S, additional, Bouguen, G, additional, Viennot, S, additional, Benjamin, P, additional, and Fumery, M, additional

Published
2020
Full Text
View/download PDF

48. The real-life experience of vedolizumab therapy in the OBSERV-IBD cohort: a 3-year prospective observational multi-centre cohort study

Author

Amiot, A., Serrero, M., Peyrin-Biroulet, L., Filippi, J., Pariente, B., Roblin, X., Buisson, Anthony, Stefanescu, C., Trang-Poisson, C., Altwegg, R., Marteau, P., Vaysse, T., Bourrier, A., Nancey, S., Laharie, D., Allez, M., Savoye, G., Moreau, J., Vuitton, L., Viennot, S., Aubourg, A., Pelletier, A. -L., Bouguen, G., Abitbol, V., Fumery, Mathurin, Gagniere, C., Bouhnik, Y., CHU Henri Mondor [Créteil], Service de Gastro-entérologie [CHU Hôpital Nord - Marseille], Hôpital Nord [CHU - APHM]-Assistance publique Hôpitaux de Marseille (APHM), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastro-entérologie et Hépatologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), CHU Clermont-Ferrand, Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut des Maladies de l'Appareil Digestif, Université de Nantes (UN), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Hépato-gastro-entérologie [APHP Kremlin-Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), STMicroelectronics [Crolles] (ST-CROLLES), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, European Crohn’s and Colitis Organisation, CHU Henri Mondor, Service de gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

49. Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study

Author

Pineton de Chambrun, G., Pariente, B., Seksik, P., Altwegg, R., Vuitton, L., Stefasnescu, C, Nancey, S., Aubourg, A, Serrero, M, Peyrin-Biroulet, L., Filippi, J., Viennot, S, Abitbol, V., Boualit, M., Boureille, A, Moreau, J., Buisson, A., Roblin, X., Nachury, M., Zappa, M., Lambert, J., Bouhnik, Y., Study Group, Getaid-Mica, Herrada, Anthony, Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Département d'hépato-gastro-entérologie [Hôpital Trousseau : CHRU Tours], CHU Trousseau [APHP], Hôpital Nord [CHU - APHM], Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier [Valenciennes, Nord], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Clermont-Ferrand, Service de gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Service de biostatistiques et information médicale [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université de Montpellier (UM)-CHU Saint-Eloi, Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-CHU Trousseau [APHP], CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)-CHU Trousseau [APHP], and Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]

Subjects
0301 basic medicine, medicine.medical_specialty, medicine.medical_treatment, 03 medical and health sciences, 0302 clinical medicine, medicine, Adalimumab, Abscess, Crohn's disease, business.industry, General surgery, Gastroenterology, Abdominal Abscess, Intra-abdominal Abscess, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, General Medicine, Bowel resection, medicine.disease, Crohn's Disease Activity Index, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, 3. Good health, 030104 developmental biology, 030211 gastroenterology & hepatology, business, Cohort study, medicine.drug
Abstract

International audience; doi:10.1093/ecco-jcc/jjy222 Abstract P528 from the 'Poster presentations' section of the main abstract book has been withdrawn and re-inserted as DOP63 in the 'Late-breaking abstracts' section.

Published
2019

50. Combining Dithienosilole-Based Organic Dyes with a Brookite/Platinum Photocatalyst toward Enhanced Visible-Light-Driven Hydrogen Production

Author

Bettucci, O, Skaltsas, T, Calamante, M, Dessì, A, Bartolini, M, Sinicropi, A, Filippi, J, Reginato, G, Mordini, A, Fornasiero, P, Zani, L, Ottavia Bettucci, Theodosis Skaltsas, Massimo Calamante, Alessio Dessì, Matteo Bartolini, Adalgisa Sinicropi, Jonathan Filippi, Gianna Reginato, Alessandro Mordini, Paolo Fornasiero, Lorenzo Zani, Bettucci, O, Skaltsas, T, Calamante, M, Dessì, A, Bartolini, M, Sinicropi, A, Filippi, J, Reginato, G, Mordini, A, Fornasiero, P, Zani, L, Ottavia Bettucci, Theodosis Skaltsas, Massimo Calamante, Alessio Dessì, Matteo Bartolini, Adalgisa Sinicropi, Jonathan Filippi, Gianna Reginato, Alessandro Mordini, Paolo Fornasiero, and Lorenzo Zani

Abstract

Dye-sensitized photocatalytic hydrogen generation is emerging as a promising process to produce fuels using a clean and abundant energy source such as sunlight. In the first part of this work, three organic dyes featuring a dithieno[3,2-b:2',3'-d]silole heterocyclic unit (OB1-OB3), bearing different substituents on various parts of the molecular scaffold, were synthesized, characterized, and used as sensitizers for the commercially available benchmark TiO2 (P25), first in dye-sensitized solar cells and then for the photocatalyzed production of hydrogen with triethanolamine as a sacrificial electron donor. In the second part of the study, aiming to improve the efficiency of the photocatalytic system, P25 was replaced with the less investigated brookite TiO2 polymorph. The photocatalyst obtained upon sensitization with the best performing dye, OB2, still in the presence of Pt as co-catalyst, displayed an enhanced performance in hydrogen production compared to that based on P25 at a lower dye loading. Extended time experiments confirmed that the catalyst was still significantly active after 1 week under continuous illumination, providing a maximum TON of 4201. The higher efficiency of the brookite-based catalytic system and its prolonged stability are especially significant in the perspective of the practical application of the dye-sensitized photocatalytic H-2 production technology.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results